Document Detail

New combination bronchodilators for COPD: current evidence and future perspectives.
MedLine Citation:
PMID:  25377687     Owner:  NLM     Status:  Publisher    
Fixed-dose combination (FDC) dual bronchodilators that co-administer a long-acting β2 agonist (LABA) and a long-acting muscarinic antagonist (LAMA) are a new class of inhaled treatment for chronic obstructive pulmonary disease (COPD). This review focuses on the clinical evidence for the benefit of LABA/LAMA FDC compared to monocomponent treatments, and also compared to active comparators that are widely used for the treatment of COPD-namely tiotropium and salmeterol-fluticasone. Novel FDC dual bronchodilators include QVA149 and umeclidinium/vilanterol (UMEC/VI). Long-term clinical trials show that QVA149 and UMEC/VI are superior to monocomponent therapy in terms of trough forced expiratory volume in 1 second (FEV1 ), although the FEV1 improvement was limited to approximately 80-90% of the added monocomponent values; this suggests that the effect of combining a LABA and a LAMA is not fully additive. LABA/LAMA FDC were associated with the largest mean changes in symptoms and health status that were above the minimal clinically important difference, in contrast to the monocomponents. Furthermore, these LABA/LAMA FDC demonstrated superiority over the active comparators tiotropium and salmeterol-fluticasone in terms of trough FEV1 and patient-reported outcomes. LABA/LAMA FDC offer a simplified means of maximising bronchodilation for COPD patients, with the improvements in lung function being mirrored by benefits in terms of symptoms and exacerbations. The use of LABA/LAMA FDC in clinical practice is set to grow, and further studies are needed to define their optimal place in treatment guidelines.
Dave Singh
Related Documents :
17555947 - A multicentre, randomized, naturalistic, open-label study between aripiprazole and stan...
20679257 - Ethical dilemmas: should antipsychotics ever be prescribed for people with dementia?
8803657 - Pharmacological treatment strategies in acute schizophrenia.
15989577 - Sertindole (serdolect): preclinical and clinical findings of a new atypical antipsychotic.
19773287 - The time has come to limit the placebo period in rheumatoid arthritis trials to 3 month...
8155097 - Is atypical odontalgia a psychological problem?
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-11-6
Journal Detail:
Title:  British journal of clinical pharmacology     Volume:  -     ISSN:  1365-2125     ISO Abbreviation:  Br J Clin Pharmacol     Publication Date:  2014 Nov 
Date Detail:
Created Date:  2014-11-7     Completed Date:  -     Revised Date:  2014-11-8    
Medline Journal Info:
Nlm Unique ID:  7503323     Medline TA:  Br J Clin Pharmacol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
This article is protected by copyright. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Mesoporosity changes from cambium to mature tension wood: a new step toward the understanding of mat...
Next Document:  Myocardial fat overgrowth in Proteus syndrome.